Where does stocks-llm's data on CDXS come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like CDXS →

CODEXIS INC (CDXS)

Health Care · Enzyme engineering and biocatalysis for pharmaceutical manufacturing · NASDAQ

Codexis engineers custom enzymes using AI-driven directed evolution to transform drug manufacturing efficiency for RNAi and small-molecule therapeutics.

View SEC filings Website Yahoo Finance Find companies like CDXS → Ask about CDXS →

What CODEXIS INC does

Codexis is a leading provider of technology solutions for therapeutics manufacturing that uses its proprietary CodeEvolver directed evolution platform to discover, develop, and commercialize novel, high-performance enzymes optimized for specific pharmaceutical applications. The company operates two main business segments: the ECO Synthesis manufacturing platform for enabling large-scale production of RNAi (RNA interference) therapeutics like siRNA drugs, and small molecule pharma biocatalysis serving major pharmaceutical companies seeking more efficient enzyme-based manufacturing processes. Through directed evolution technology combining machine learning with molecular and cellular workflows, Codexis designs and optimizes enzyme variants to improve yield, purity, specificity, stability, and manufacturing efficiency while reducing costs and waste.

Themes: ["RNAi therapeutics manufacturing","Enzyme engineering / protein optimization","Pharmaceutical manufacturing efficiency","Biocatalysis / green chemistry","AI-driven drug development","Gene therapy / RNA interference"]

Fundamentals

Price$2.56 as of 2026-07-09 close
Market cap$236M as of 2026-07-10
1-year return-12.0% as of 2026-07-09 close
Net margin-41.0% as of 2026-07-10
Gross margin+88.9% as of 2026-07-10
ROE-68.1% as of 2026-07-10
Debt / equity0.94 as of 2026-07-10
Revenue growth (YoY)+56.8% as of 2026-07-10
Revenue CAGR (3y)-20.2% SEC XBRL
Beta2.47 as of 2026-07-10

Ask why CDXS looks like this →

Key risks (from latest filing)

["Reliance on partnerships with CDMOs (contract development and manufacturing organizations) to commercialize ECO Synthesis platform at scale; partnerships remain in early feasibility stage with no guaranteed advancement to GMP production","RNAi therapeutics market growth and adoption uncertainty; ECO Synthesis platform success depends on customer demand and regulatory approval of siRNA-based drugs","Significant operating losses and negative net margins (-40.96%); company is unprofitable and dependent on continued capital funding and revenue growth to achieve profitability"]

See CDXS's biggest risks from its latest 10-Q →

Competitors & peers

Genentech (Roche)
Evonik Industries
DSM-Firmenich
Intrexon (now Precigen)
Synthego
Sartorius

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.